Adjuvant Sutent improves disease-free survival in RCC

Pfizer Inc. (NYSE:PFE) said Sutent sunitinib met the primary endpoint of significantly improving

Read the full 133 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE